Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 1
2012 1
2013 2
2014 5
2015 1
2016 3
2017 4
2018 4
2019 8
2020 12
2021 18
2022 18
2023 12

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia.
Xiao W, Chan A, Waarts MR, Mishra T, Liu Y, Cai SF, Yao J, Gao Q, Bowman RL, Koche RP, Csete IS, DelGaudio NL, Derkach A, Baik J, Yanis S, Famulare CA, Patel M, Arcila ME, Stahl M, Rampal RK, Tallman MS, Zhang Y, Dogan A, Goldberg AD, Roshal M, Levine RL. Xiao W, et al. Among authors: derkach a. Blood. 2021 Mar 11;137(10):1377-1391. doi: 10.1182/blood.2020007897. Blood. 2021. PMID: 32871587 Free PMC article.
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.
Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King AC, Daniyan AF, Famulare C, Cuello BM, Horvat TZ, Abdel-Wahab O, Levine RL, Viny AD, Stein EM, Cai SF, Roshal M, Tallman MS, Goldberg AD. Stahl M, et al. Among authors: derkach a. Blood Adv. 2021 Mar 9;5(5):1552-1564. doi: 10.1182/bloodadvances.2020003734. Blood Adv. 2021. PMID: 33687434 Free PMC article.
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Bewersdorf JP, et al. Among authors: derkach a. Leuk Lymphoma. 2021 Dec;62(14):3394-3401. doi: 10.1080/10428194.2021.1966788. Epub 2021 Sep 3. Leuk Lymphoma. 2021. PMID: 34477024 Free PMC article.
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O, Hultcrantz M, Diamond B, Lesokhin AM, Mailankody S, Hassoun H, Tan C, Shah UA, Lu SX, Salcedo M, Werner K, Rispoli J, Caple J, Sams A, Verducci D, Jones K, Concepcion I, Ciardello A, Chansakul A, Schlossman J, Tavitian E, Shekarkhand T, Harrison A, Piacentini C, Rustad EH, Yellapantula V, Maclaughlan K, Maura F, Landau HJ, Scordo M, Chung DJ, Shah G, Lahoud OB, Thoren K, Murata K, Ramanathan L, Arcila ME, Ho C, Roshal M, Dogan A, Derkach A, Giralt SA, Korde N. Landgren O, et al. Among authors: derkach a. JAMA Oncol. 2021 Jun 1;7(6):862-868. doi: 10.1001/jamaoncol.2021.0611. JAMA Oncol. 2021. PMID: 33856405 Free PMC article. Clinical Trial.
Clonal hematopoiesis is associated with risk of severe Covid-19.
Bolton KL, Koh Y, Foote MB, Im H, Jee J, Sun CH, Safonov A, Ptashkin R, Moon JH, Lee JY, Jung J, Kang CK, Song KH, Choe PG, Park WB, Kim HB, Oh MD, Song H, Kim S, Patel M, Derkach A, Gedvilaite E, Tkachuk KA, Wiley BJ, Chan IC, Braunstein LZ, Gao T, Papaemmanuil E, Esther Babady N, Pessin MS, Kamboj M, Diaz LA Jr, Ladanyi M, Rauh MJ, Natarajan P, Machiela MJ, Awadalla P, Joseph V, Offit K, Norton L, Berger MF, Levine RL, Kim ES, Kim NJ, Zehir A. Bolton KL, et al. Among authors: derkach a. Nat Commun. 2021 Oct 13;12(1):5975. doi: 10.1038/s41467-021-26138-6. Nat Commun. 2021. PMID: 34645798 Free PMC article.
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.
Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, Gill SI, Manning BM, Koprivnikar J, McCloskey J, Testi R, Prebet T, Al Ali NH, Padron E, Sallman DA, Komrokji RS, Goldberg AD. Ball BJ, et al. Among authors: derkach a. Blood Adv. 2020 Jul 14;4(13):2866-2870. doi: 10.1182/bloodadvances.2020001482. Blood Adv. 2020. PMID: 32589727 Free PMC article.
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
Stahl M, Derkach A, Farnoud N, Bewersdorf JP, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel MA, Cai SF, Miles LA, Bowman RL, Geyer MB, Dunbar A, Epstein-Peterson ZD, McGovern E, Schulman J, Glass JL, Taylor J, Viny AD, Stein EM, Getta B, Arcila ME, Gao Q, Barker J, Shaffer BC, Papadopoulos EB, Gyurkocza B, Perales MA, Abdel-Wahab O, Levine RL, Giralt SA, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman MS, Roshal M, Goldberg AD. Stahl M, et al. Among authors: derkach a. Am J Hematol. 2023 Jan;98(1):79-89. doi: 10.1002/ajh.26757. Epub 2022 Oct 31. Am J Hematol. 2023. PMID: 36251406
Group testing in mediation analysis.
Derkach A, Moore SC, Boca SM, Sampson JN. Derkach A, et al. Stat Med. 2020 Aug 15;39(18):2423-2436. doi: 10.1002/sim.8546. Epub 2020 May 4. Stat Med. 2020. PMID: 32363646 Free PMC article.
79 results